Genomics plc Launches MySTra AI for Predictive Genetics
Genomics plc has launched MySTra AI, a platform that applies artificial intelligence to large-scale genetic data to generate polygenic scores for disease risk prediction. The company positions MySTra AI as a tool for translating complex genomic patterns into actionable risk estimates for research, clinical study design, and therapeutic discovery.
AI-Driven Polygenic Scores for Disease Risk
MySTra AI uses machine learning models trained on population-scale genomic and phenotype datasets to calculate polygenic scores. Polygenic scores aggregate the small effects of many genetic variants into a single metric that estimates an individual’s inherited risk for common conditions. According to Genomics plc, the platform aims to improve the accuracy and calibrations of these scores across traits and cohorts, supporting risk stratification for conditions such as cardiovascular disease, diabetes, and common cancers.
Impact on Drug Discovery and Personalized Medicine
For drug developers, MySTra AI can help identify genetic signals linked to disease biology and prioritize targets with human genetic support. Polygenic stratification can refine cohort selection for trials, increase power to detect drug effects, and inform biomarker strategies. In clinical settings, better genetic risk estimates can guide preventive strategies and tailor monitoring intensity, supporting more personalized care pathways when combined with clinical and lifestyle data.
The Future of AI in Genetic Prediction
MySTra AI exemplifies a broader trend of AI-driven interpretation of genomics. The platform highlights opportunities to scale predictive genetics, but wider adoption will depend on external validation, transparent performance across ancestries, and regulatory pathways for clinical use. As AI models and datasets expand, expect continued improvements in prediction fidelity and further integration into research and therapeutic development workflows.
Genomics plc’s MySTra AI underscores how AI is being applied to make genomic signals more interpretable and actionable for healthcare and drug discovery stakeholders.
